日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial

流感和新冠病毒多组分疫苗在50岁及以上成年人中的免疫原性和安全性:一项随机临床试验

Rudman Spergel, Amanda K; Wu, Iris; Deng, Weiping; Cardona, Jose; Johnson, Kimball; Espinosa-Fernandez, Ivette; Sinkiewicz, Melissa; Urdaneta, Veronica; Carmona, Lizbeth; Schaefers, Kristin; Girard, Bethany; Paila, Yamuna D; Mehta, Darshan; Callendret, Benoit; Kostanyan, Lusine; Ananworanich, Jintanat; Miller, Jacqueline; Das, Rituparna; Shaw, Christine A

Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3

腺病毒载体RSV融合前糖蛋白+可溶性糖蛋白联合免疫可建立持久的IgG3调理吞噬抗体反应。

Tong, Xin; Blanc, Ross; Cizmeci, Deniz; Malca, Hadar; Kang, Jaewon; Comeaux, Christy; Callendret, Benoit; Bastian, Arangassery Rosemary; Khan, Mehak Zahoor; Alter, Galit; Lingwood, Daniel; McNamara, Ryan P

Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge.

Ad26.RSV.preF 可完全保护小牛免受牛呼吸道合胞病毒 (RSV) 感染引起的严重呼吸道疾病

van der Fits Leslie, de Jong Rineke, Dijkman Karin, Heemskerk-van der Meer Marjolein, Tettero Lisanne, Bonsing Judith, van Oort Sophie, Serroyen Jan, van Schie Marianke, Stockhofe-Zurwieden Norbert, Callendret Benoit, Zahn Roland

Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial

在65岁及以上成人中同时接种Ad26.RSV.preF/RSV preF蛋白疫苗和高剂量流感疫苗:一项非劣效性试验

Widagdo, Widagdo; Bastian, Arangassery Rosemary; Jastorff, Archana M; Scheys, Ilse; De Paepe, Els; Comeaux, Christy A; Ligtenberg, Nynke; Callendret, Benoit; Heijnen, Esther

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older

一项随机、双盲、安慰剂对照的I期研究,旨在评估基于Ad26.RSV.preF的单次疫苗接种方案在日本60岁及以上成年人中的安全性、反应原性和免疫原性。

Eto, Takashi; Okubo, Yusuke; Momose, Atsushi; Tamura, Hiroshi; Zheng, Richuan; Callendret, Benoit; Bastian, Arangassery Rosemary; Comeaux, Christy A

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months

一项评估Ad26.RSV.preF在12-24个月龄RSV血清阴性幼儿中的安全性和免疫原性的1/2a期研究

Langley, Joanne M; Nolan, Terry M; Rämet, Mika; Richmond, Peter C; Rosário Filho, Nelson; Haazen, Wouter; van den Berg, Sara P H; Williams, Kristi; Bastian, Arangassery Rosemary; Omoruyi, Edmund; Williams Durkin, Joanna; Salisch, Nadine; Van Geet, Gunter; van Duijnhoven, Wilbert; Heijnen, Esther; Callendret, Benoit

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

在预测的中期和末期保质期内,评估Ad26.RSV.preF/RSV preF蛋白疫苗的免疫原性和安全性,以此评价其在整个保质期内的效力。

Hosman, Tessa; van Heesbeen, Roy; Bastian, Arangassery Rosemary; Hu, Weihong; Comeaux, Christy; Ligtenberg, Nynke; van Montfort, Bart; Callendret, Benoît; Heijnen, Esther

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

Ad26.RSV.preF/RSV preF 蛋白疫苗在 60 至 75 岁成人中的免疫原性、安全性和反应原性:2b 期和 3 期临床试验材料的比较

Jastorff, Archana; Bastian, Arangassery Rosemary; Ligtenberg, Nynke; Klyashtornyy, Vladislav; Callendret, Benoît; Heijnen, Esther

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models

在临床前模型中,Ad26.RSV.preF/preF 蛋白联合疫苗比单一疫苗组分能诱导更强的保护性免疫。

Eirikur Saeland ,Leslie van der Fits ,Renske Bolder ,Marjolein Heemskerk-van der Meer ,Joke Drijver ,Yolinda van Polanen ,Cornelis Vaneman ,Lisanne Tettero ,Freek Cox ,Jan Serroyen ,Matthew J Jorgensen ,Johannes P M Langedijk ,Hanneke Schuitemaker ,Benoit Callendret ,Roland C Zahn

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

免疫记忆的持久性可能是人类接种疫苗后获得长期埃博拉病毒病保护作用的潜在相关因素

McLean, Chelsea; Dijkman, Karin; Gaddah, Auguste; Keshinro, Babajide; Katwere, Michael; Douoguih, Macaya; Robinson, Cynthia; Solforosi, Laura; Czapska-Casey, Dominika; Dekking, Liesbeth; Wollmann, Yvonne; Volkmann, Ariane; Pau, Maria Grazia; Callendret, Benoit; Sadoff, Jerry; Schuitemaker, Hanneke; Zahn, Roland; Luhn, Kerstin; Hendriks, Jenny; Roozendaal, Ramon